F

Faes Farma SA
MAD:FAE

Watchlist Manager
Faes Farma SA
MAD:FAE
Watchlist
Price: 4.31 EUR -0.58% Market Closed
Market Cap: 1.4B EUR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one FAE stock under the Base Case scenario is 4.53 EUR. Compared to the current market price of 4.31 EUR, Faes Farma SA is Undervalued by 5%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

FAE Relative Value
Base Case
4.53 EUR
Undervaluation 5%
Relative Value
Price
F
Worst Case
Base Case
Best Case

Valuation Multiples

2.7
P/S
P/S
Price to Sales
2.7
vs History
7
vs Industry
48
Median 3Y
2.4
Median 5Y
2.4
Industry
2.4
Forward
2.5
More Details
12
P/E
P/E
Price to Earnings
12
vs History
34
vs Industry
37
Median 3Y
11.4
Median 5Y
11.7
Industry
20.3
Forward
13.2
More Details
11.6
P/OCF
P/OCF
Price to OCF
11.6
vs History
39
vs Industry
37
Median 3Y
10.3
Median 5Y
10.8
Industry
15.6
More Details
17.8
P/FCFE
P/FCFE
Price to FCFE
17.8
vs History
61
vs Industry
19
Median 3Y
22.6
Median 5Y
22.6
Industry
23.1
More Details
1.8
P/B
P/B
Price to Book Value
1.8
vs History
42
vs Industry
46
Median 3Y
1.7
Median 5Y
1.8
Industry
2
More Details
2.6
EV/S
EV/S
Enterprise Value to Sales
2.6
vs History
3
vs Industry
47
Median 3Y
2.2
Median 5Y
2.3
Industry
2.5
Forward
2.4
More Details
3.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.9
vs History
9
vs Industry
56
Median 3Y
3.4
Median 5Y
3.5
Industry
4.8
More Details
10
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
10
vs History
0
vs Industry
37
Median 3Y
8.3
Median 5Y
8.3
Industry
12.5
Forward
9.3
More Details
11.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
11.8
vs History
0
vs Industry
38
Median 3Y
9.8
Median 5Y
9.7
Industry
15.7
Forward
11.8
More Details
11.1
EV/OCF
EV/OCF
Enterprise Value to OCF
11.1
vs History
33
vs Industry
38
Median 3Y
9.8
Median 5Y
10.3
Industry
14.1
More Details
16.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
16.9
vs History
57
vs Industry
20
Median 3Y
21.3
Median 5Y
19.3
Industry
17.6
More Details
1.8
EV/IC
EV/IC
Enterprise Value to IC
1.8
vs History
52
vs Industry
43
Median 3Y
1.6
Median 5Y
1.8
Industry
1.8
More Details

Multiples Across Competitors

FAE Competitors Multiples
Faes Farma SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
ES
Faes Farma SA
MAD:FAE
1.3B EUR 2.7 12 10 11.8
US
Eli Lilly and Co
NYSE:LLY
734.6B USD 15 66.1 35.5 38.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
371.6B USD 4.2 17 12.5 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.7 19.4 12.8 14.6
CH
Roche Holding AG
SIX:ROG
215.9B CHF 3.6 26.1 9.8 11.4
UK
AstraZeneca PLC
LSE:AZN
165.9B GBP 4 28.5 130.9 197.4
CH
Novartis AG
SIX:NOVN
182.1B CHF 4.1 17.2 10.1 13.6
US
Merck & Co Inc
NYSE:MRK
199.8B USD 3.1 11.5 8.2 9.9
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
120.1B EUR 1.3 9.5 5.2 6.1
P/E Multiple
Earnings Growth PEG
ES
F
Faes Farma SA
MAD:FAE
Average P/E: 23
12
0%
N/A
US
Eli Lilly and Co
NYSE:LLY
66.1
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.4
18%
1.1
CH
Roche Holding AG
SIX:ROG
26.1
32%
0.8
UK
AstraZeneca PLC
LSE:AZN
28.5
36%
0.8
CH
Novartis AG
SIX:NOVN
17.2
17%
1
US
Merck & Co Inc
NYSE:MRK
11.5
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
9.5
28%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
ES
F
Faes Farma SA
MAD:FAE
Average EV/EBITDA: 394.8
10
6%
1.7
US
Eli Lilly and Co
NYSE:LLY
35.5
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
12.8
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.8
6%
1.6
UK
AstraZeneca PLC
LSE:AZN
130.9
9%
14.5
CH
Novartis AG
SIX:NOVN
10.1
5%
2
US
Merck & Co Inc
NYSE:MRK
8.2
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.2
8%
0.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
ES
F
Faes Farma SA
MAD:FAE
Average EV/EBIT: 1 698
11.8
8%
1.5
US
Eli Lilly and Co
NYSE:LLY
38.8
33%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.3
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.6
14%
1
CH
Roche Holding AG
SIX:ROG
11.4
6%
1.9
UK
AstraZeneca PLC
LSE:AZN
197.4
21%
9.4
CH
Novartis AG
SIX:NOVN
13.6
10%
1.4
US
Merck & Co Inc
NYSE:MRK
9.9
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
6.1
14%
0.4

See Also

Summary
FAE intrinsic value, competitors valuation, and company profile.
DCF Valuation
FAE stock valuation using Discount Cash Flow valuation method.
Relative Valuation
FAE stock valuation using valuation multiples.
Wall Street Estimates
FAE price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
FAE stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 252,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.